Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment
A Prospective, Non-interventional Study of Different First-line Immunotherapy in Advanced Hepatocellular Carcinoma Patients: Efficacy and Immune Microenvironment Dynamics
Fudan University
150 participants
Sep 1, 2025
OBSERVATIONAL
Conditions
Summary
To evaluate the efficacy and immune microenvironment changes in advanced hepatocellular carcinoma (HCC) patients receiving different first-line immunotherapy.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Sintilimab will be administered by IV, 200 mg every 3 weeks
Bevacizumab biosimilar will be administered by IV, 15 mg/kg every 3 weeks.
Camrelizumab will be administered by IV, 200 mg every 2 weeks.
Rivoceranib will be administered by oral 250 mg once daily.
Nivolumab will be administered by IV, 1 mg/kg every 3 weeks for up to four doses, followed by nivolumab 480 mg every 4 weeks
Ipilimumab will be administered by IV, 3mg/kg every 3 weeks for up to four doses.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07147101